home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.53 +0.02 (+0.04%)

Official Closing Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

45 46 Next >

3 High Dividend Stocks With Attractive Total Return Potential ↗

March 10, 2023

In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.

Via InvestorPlace

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race ↗

March 08, 2023

These companies aren't working on a vaccine, but a monoclonal antibody.

Via Investor's Business Daily

Schrodinger is an AI-Powered Drug Discovery Developer to Watch

March 08, 2023

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

Via MarketBeat

Topics Artificial Intelligence

Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock? ↗

March 05, 2023

This vaccine candidate could help tackle the respiratory syncytial virus.

Via The Motley Fool

March 2023 Stock Considerations ↗

March 04, 2023

The calendar has turned, and a new trading month is upon us. 2023 is flying by as two months are already in the books, and that fact simply highlights the importance of staying invested in the stock...

Via Talk Markets

GSK CEO Emma Walmsley On Beating Q4 Earnings ↗

February 01, 2023

GSK came out with quarterly earnings of $0.64 per share.

Via Talk Markets

GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine ↗

February 01, 2023

Via Benzinga

Preview: GlaxoSmithKline's Earnings ↗

January 31, 2023

Via Benzinga

FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's ↗

March 02, 2023

Via Benzinga

3 Crucial Things to Know About Moderna Right Now ↗

February 27, 2023

This vaccine leader is preparing for a post-pandemic world.

Via The Motley Fool

GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023 ↗

February 24, 2023

The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months.

Via Benzinga

Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields ↗

February 23, 2023

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows ↗

February 23, 2023

Via Benzinga

Intel and 9 Other Companies With Dividend Cuts in 2023 ↗

February 22, 2023

Intel announced that it would cut its dividend by a whopping 66%. Here are nine other companies that have also seen dividend cuts this year.

Via InvestorPlace

Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029

February 22, 2023

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END

Via FinancialNewsMedia

My 3 Biggest Stock Market Predictions for March ↗

February 21, 2023

These three trends will likely drive revenue and share prices.

Via The Motley Fool

EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue ↗

February 15, 2023

Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among...

Via Benzinga

JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals ↗

February 15, 2023

Via Benzinga

Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗

February 14, 2023

Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.

Via Benzinga

Dividend Income Update For January 2023 ↗

February 12, 2023

Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how...

Via Talk Markets

Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass ↗

February 11, 2023

CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global...

Via Talk Markets

FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting ↗

February 10, 2023

Via Benzinga

FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer ↗

February 10, 2023

Via Benzinga

Is Biotech Immunocore About To Make A 25% Price Move?

February 07, 2023

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

Via MarketBeat

Topics ETFs

February 2023 Stock Considerations ↗

February 05, 2023

With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks...

Via Talk Markets

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease ↗

February 02, 2023

Via Benzinga

Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗

February 01, 2023

Two of the three companies easily beat sales and earnings expectations, but sales fell for the third.

Via Investor's Business Daily

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Earnings Scheduled For February 1, 2023 ↗

February 01, 2023

Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com